Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Is cimzia an option for patients with latex allergy?
If not, are there other TNFi that do not contain latex?
Related Questions
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
If subdeltoid bursitis, bicipital tenosynovitis, and femoroacetabular synovitis are commonly present in PMR, why are they not included in the criteria for PMR and how are they differentiated from elderly onset RA where presentation is often atypical and more proximal?
What is your typical steroid taper regimen for managing RA flares?
How do you assess the potential role of obesity in driving inflammatory joint symptoms?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
When do you recommend initiation of targeted therapies in active RA with history of malignancy?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?